Mexilon (Meloxicam)

Meloxicam works by selectively inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins—chemical mediators that cause inflammation, pain, and fever. By lowering prostaglandin levels at sites of tissue injury, meloxicam diminishes the inflammatory response and associated discomfort.

The dosage of Mexilon is determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of symptoms, and individual risk factors. The prescriber will select the appropriate amount and frequency according to current medical guidelines and the patient’s response to therapy.

The safety of meloxicam during pregnancy and lactation has not been established, and the product’s pregnancy category is listed as unknown. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Mexilon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Mexilon (meloxicam) offers a longer half‑life and greater COX‑2 selectivity compared with many traditional NSAIDs such as ibuprofen or diclofenac. This can allow once‑daily dosing and may reduce gastrointestinal side effects, although individual tolerance varies. Clinicians choose meloxicam when a sustained anti‑inflammatory effect is desired with a potentially lower risk of gastric irritation.

Mexilon should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain to preserve stability and potency.

Mexilon is supplied as an injectable solution for intramuscular (IM) administration. A qualified healthcare professional injects the prescribed dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique. The injection site should be monitored for local reactions after administration.

Serious risks include gastrointestinal ulceration or bleeding, severe skin reactions such as Stevens‑Johnson syndrome, acute renal impairment, cardiovascular events like myocardial infarction, and anaphylactic reactions. Patients should be educated to seek immediate medical attention if they experience symptoms such as severe abdominal pain, rash, swelling, difficulty breathing, or sudden loss of kidney function.

Mexilon is contraindicated in patients with known hypersensitivity to meloxicam or any other NSAIDs, those with active gastrointestinal bleeding or ulceration, and individuals with severe renal or hepatic impairment. It should also be avoided in patients who have experienced a previous severe cardiovascular event related to NSAID use.